Loading clinical trials...
Loading clinical trials...
A Phase III Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula Polymorpha) in Healthy People Aged 6 Months to 13 Years
Conditions
Interventions
Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)
placebo
Locations
3
China
Laishui County Center for Disease Control and Prevention
Baoding, Hebei, China
Jingxing County Center for Disease Control and Prevention
Shijiazhuang, Hebei, China
Zhao County Center for Disease Control and Prevention
Shijiazhuang, Hebei, China
Start Date
June 30, 2023
Primary Completion Date
July 27, 2025
Completion Date
July 27, 2025
Last Updated
January 16, 2026
NCT06944717
NCT07254728
NCT05213728
NCT04875676
NCT06211621
NCT04941261
Lead Sponsor
National Vaccine and Serum Institute, China
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions